Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Safety and Pharmacokinetics of Apixaban Versus Vitamin K Antagonist (VKA) or Low Molecular Weight Heparin (LMWH) in Pediatric Subjects With Congenital or Acquired Heart Disease Requiring Anticoagulation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com~Inclusion Criteria:~* Males and Females, 28 days to \< 18 years of age, inclusive~* Congenital or acquired heart diseases requiring chronic anticoagulation for thromboprophylaxis (eg, single ventricle physiology including all 3 stages of palliation, dilated cardiomyopathy, Kawasaki disease with coronary aneurysms, and pulmonary hypertension)~* Eligible participants include those who newly start anticoagulants and those who are currently on VKA or LMWH or other anticoagulants for thromboprophylaxis~* Able to tolerate enteral medication \[eg, by mouth, nasogastric tube, or gastric tube\]~* Participants 28 days to \< 3 months must be able to tolerate oral/nasogastric tube (NGT)/gastric tube (GT) feeds for at least 5 days prior to randomization~Exclusion Criteria:~* Recent thromboembolic events less than 6 months prior to enrollment~* Weight \< 3 kg~* Use of aggressive life-saving therapies such as ventricular assist devices (VAD) or extracorporeal membrane oxygenation (ECMO) at the time of enrollment~* Artificial heart valves and mechanical heart valves~* Known inherited bleeding disorder or coagulopathy (e.g. hemophilia, von Willebrand disease, etc.)~* Active bleeding at the time of enrollment~* Any major bleeding other than perioperative in the preceding 3 months~* Known intracranial congenital vascular malformation or tumor~* Confirmed diagnosis of a GI ulcer~* Known antiphospholipid syndrome (APS).~Other protocol defined inclusion/exclusion criteria apply

- Gender: ALL
- Minimum Age: 28 Days
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Apixaban (Type: EXPERIMENTAL): None
- LMWH/VKA (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).